Matches in Nanopublications for { ?s ?p "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP1266650.RAWRoU_H0zWufk-KojqzQHOEmyCXS_BOeuLjFJkeIodWs130_assertion description "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266650.RAWRoU_H0zWufk-KojqzQHOEmyCXS_BOeuLjFJkeIodWs130_provenance.
- NP1266646.RApcG5F1b6GRBdHZ7ksOdZPMVcfl3cKNN6DvYUkghbRRE130_assertion description "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266646.RApcG5F1b6GRBdHZ7ksOdZPMVcfl3cKNN6DvYUkghbRRE130_provenance.
- NP1266651.RAsl9x_qFah6wlacz6SFUEwJQKuN-x436Ilq79nak9a8o130_assertion description "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266651.RAsl9x_qFah6wlacz6SFUEwJQKuN-x436Ilq79nak9a8o130_provenance.
- NP1266652.RAl4Vau80-YCan3KaA1m4rWpPWouQBtQsn6KmKzuNGQBg130_assertion description "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266652.RAl4Vau80-YCan3KaA1m4rWpPWouQBtQsn6KmKzuNGQBg130_provenance.
- NP1266653.RAiwGXgEYmIMsBSK-pK8PbbPW-H65rtB8OEZe0oM3Dux4130_assertion description "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266653.RAiwGXgEYmIMsBSK-pK8PbbPW-H65rtB8OEZe0oM3Dux4130_provenance.
- NP1266654.RAmnlSVGlT-e1vk8JFOaSl2VpZkgfYDBnuVNpNkVZ9uf4130_assertion description "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266654.RAmnlSVGlT-e1vk8JFOaSl2VpZkgfYDBnuVNpNkVZ9uf4130_provenance.
- NP1266648.RAKTD0JA92mp5UGZFKmTnSguoOQPdjPVzszh-rX3jiQFA130_assertion description "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266648.RAKTD0JA92mp5UGZFKmTnSguoOQPdjPVzszh-rX3jiQFA130_provenance.
- NP1266647.RAzdFuqQqZBjEj1btNOj1uW3GmLpPEiH0nbt_Q-g2Dsmg130_assertion description "[Thus our preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266647.RAzdFuqQqZBjEj1btNOj1uW3GmLpPEiH0nbt_Q-g2Dsmg130_provenance.